Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 2, 2006 - Issue 3
Submit an article Journal homepage
96
Views
22
CrossRef citations to date
0
Altmetric
Review

Toxic metabolic syndrome associated with HAART

Steen B Haugaard Physician, Hvidovre University Hospital, Clinical Research Unit, Department of Endocrinology and Internal Medicine and Department of Infectious Diseases, DK 2650 Hvidovre, Copenhagen, Denmark. [email protected]
Pages 429-445 | Published online: 30 May 2006

Bibliography

  • LO JC, MULLIGAN K, TAI VW, ALGREN H, SCHAMBELAN M: Buffalo hump in men with HIV-1 infection. Lancet (1998) 351(9106):867-870.
  • VIRABEN R, AQUILINA C: Indinavir-associated lipodystrophy. AIDS (1998) 12(6):F37-F39.
  • CARR A, SAMARAS K, BURTON S etal.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 12(7):F51-F58.
  • KOTLER DP, TIERNEY AR, WANG J, PIERSON RN Jr: Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am. J. Clin. Nutr. (1989) 50(3):444-447.
  • MOCROFT A, VELLA S, BENFIELD TL etal.: Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet (1998) 352(9142):1725-1730.
  • CARR A, SAMARAS K, THORISDOTTIR A, KAUFMANN GR, CHISHOLM DJ, COOPER DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet (1999) 353(9170):2093-2099.
  • MARTINEZ E, MOCROFT A, GARCIA-VIEJO MA etal.: Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet (2001) 357(9256):592-598.
  • SAINT-MARC T, PARTISANI M, POIZOT-MARTIN I etal.: Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS (2000) 14(1):37-49.
  • THIEBAUT R, DAUCOURT V, MERCIEP etal.: Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe dEpidemiologie Clinique du Syndrome dImmunodeficience Acquise en Aquitaine. Clin. Infect. Dis. (2000) 31(6):1482-1487.
  • BERNASCONI E, BOUBAKER K, JUNGHANS C etal.: Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J. Acquir. Immune. Defic. Syndr. (2002) 31(1):50-55.
  • BOUFASSA F, DULIOUST A, LASCAUXAS etal.: Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin. Trials (2001) 2(4):339-345.
  • SAVES M, RAFFI F, CAPEAU J etal.: Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin. Infect. Dis. (2002) 34(10):1396-1405.
  • CARR A, EMERY S, LAW M, PULS R, LUNDGREN JD, POWDERLY WG: An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 361(9359):726-735.
  • BELLOSO WH, QUIROS RE, IVALO SA etal.: Agreement analysis of variables involved in lipodystrophy syndrome definition in HIV-infected patients. J. Acquir. Immune Defic. Syndr. (2003) 32(1):104-111.
  • CARR A, MILLER J, LAW M, COOPERDA: A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS (2000) 14(3):F25-F32.
  • MARTINEZ E, BIANCHI L, GARCIA-VIEJO MA, BRU C, GATELLJM: Sonographic assessment of regional fat in HIV-1-infected people. Lancet (2000) 356(9239):1412-1413.
  • CHEN D, MISRA A, GARG A: Clinical review 153: lipodystrophy in human immunodeficiency virus- infected patients. J. Clin. Endocrinol. Metab. (2002) 87(11):4845-4856.
  • BACCHETTI P, GRIPSHOVER B, GRUNFELD C etal.: Fat distribution in men with HIV infection. J. Acquir. Immune Defic. Syndr. (2005) 40(2):121-131.
  • SAINT-MARC T, PARTISANI M, POIZOT-MARTIN I etal.: A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS (1999) 13(13):1659-1667.
  • MALLAL SA, JOHN M, MOORE CB, JAMES IR, MCKINNON EJ: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS (2000) 14(10):1309-1316.
  • VAN D, V, GISOLF EH, REISS P etal.: Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS (2001) 15(7):847-855.
  • MALLON PW, MILLER J, COOPER DA, CARR A: Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS (2003) 17(7):971-979.
  • DUBE MP, PARKER RA, TEBAS P etal.: Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS (2005) 19(16):1807-1818.
  • GRUNFELD C, PANG M, DOERRLERW, SHIGENAGA JK, JENSEN P, FEINGOLD KR: Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. (1992) 74(5):1045-1052.
  • SAFRIN S, GRUNFELD C: Fat distribution and metabolic changes in patients with HIV infection. AIDS (1999) 13(18):2493-2505.
  • FRIIS-MOLLER N, WEBER R, REISS P etal.: Cardiovascular disease risk factors in HIV patients association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 17(8):1179-1193.
  • LENHARD JM, CROOM DK, WEIELJE, WINEGAR DA: HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler. Thromb. Vasc. Biol. (2000) 20(12):2625-2629.
  • DEN BOER MA, BERBEE JF, REISS P etal.: Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue. Arterioscler. Thromb. Vasc. Biol. (2006) 26(1):124-129.
  • VAN WIJK JP, CABEZAS MC, DE KONING EJ, RABELINK TJ, VAN DER GR, HOEPELMAN IM: Invivo evidence of impaired peripheral fatty acid trapping in patients with human immunodeficiency virus-associated lipodystrophy. J. Clin. Endocrinol. Metab. (2005) 90(6):3575-3582.
  • HADIGAN C, BORGONHA S, RABE J, YOUNG V, GRINSPOON S: Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism (2002) 51(9):1143-1147.
  • HAUGAARD SB, ANDERSEN O, DELAF etal.: Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic -cells. Eur. J. Endocrinol. (2005) 152(1):103-112.
  • HAUGAARD SB, ANDERSEN O, VOLUND A etal.: -cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Clin. Endocrinol. (Oxf) (2005) 62(3):354-361.
  • SEKHAR RV, JAHOOR F, WHITE AC etal.: Metabolic basis of HIV-lipodystrophy syndrome. Am. J. Physiol. Endocrinol. Metab. (2002) 283(2):E332-E337.
  • LIANG JS, DISTLER O, COOPER DA etal.: HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat. Med. (2001) 7(12):1327-1331.
  • SCHMITZ M, MICHL GM, WALLI R etal.: Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J. Acquir. Immune Defic. Syndr. (2001) 26(3):225-235.
  • BONNET E, RUIDAVETS JB, TUECH J etal.: Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J. Clin. Endocrinol. Metab. (2001) 86(1):296-302.
  • RIMLAND D, GUEST JL, HERNANDEZ I, DEL RIO C, LE NA, BROWN WV: Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins. HIV Med. (2005) 6(5):326-333.
  • MCCONATHY WJ, GESQUIERE JC, BASS H, TARTAR A, FRUCHART JC, WANG CS: Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J. Lipid Res. (1992) 33(7):995-1003.
  • CHEN M, BRESLOW JL, LI W, LEFF T: Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J. Lipid Res. (1994) 35(11):1918-1924.
  • GRUBER PJ, TORRES-ROSADO A, WOLAK ML, LEFF T: Apo CIII gene transcription is regulated by a cytokine inducible NF-B element. Nucleic Acids Res. (1994) 22(12):2417-2422.
  • AUWERX J, SCHOONJANS K, FRUCHART JC, STAELS B: Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis (1996) 124(Suppl.):S29-S37.
  • LAMARCHE B, RASHID S, LEWIS GF: HDL metabolism in hypertriglyceridemic states: an overview. Clin. Chim. Acta (1999) 286(1-2):145-161.
  • LAMARCHE B, UFFELMAN KD, CARPENTIER A etal.: Triglyceride enrichment of HDL enhances invivo metabolic clearance of HDL apo A-I in healthy men. J. Clin. Invest. (1999) 103(8):1191-1199.
  • RIDDLER SA, SMIT E, COLE SR etal.: Impact of HIV infection and HAART on serum lipids in men. JAMA (2003) 289(22):2978-2982.
  • ROSE H, WOOLLEY I, HOY J etal.: HIV infection and high-density lipoprotein: the effect of the disease versus the effect of treatment. Metabolism (2006) 55(1):90-95.
  • VAN T WOUT AB, SWAIN JV, SCHINDLER M etal.: Nef induces multiple genes involved in cholesterol synthesis and uptake in human immunodeficiency virus type 1-infected T cells. J. Virol. (2005) 79(15):10053-10058.
  • BASTARD JP, CARON M, VIDAL H etal.: Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet (2002) 359(9311):1026-1031.
  • JAN V, CERVERA P, MAACHI M etal.: Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir. Ther. (2004) 9(4):555-564.
  • CARON M, AUCLAIR M, VIGOUROUX C, GLORIAN M, FOREST C, CAPEAU J: The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes (2001) 50(6):1378-1388.
  • CARON M, AUCLAIR M, STERLINGOT H, KORNPROBST M, CAPEAU J: Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS (2003) 17(17):2437-2444.
  • AMEMIYA-KUDO M, SHIMANO H, YOSHIKAWA T etal.: Promoter analysis of the mouse sterol regulatory element-binding protein-1c gene. J. Biol. Chem. (2000) 275(40):31078-31085.
  • SHIMOMURA I, HAMMER RE, RICHARDSON JA etal.: Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev. (1998) 12(20):3182-3194.
  • JOHNSON JA, ALBU JB, ENGELSONES etal.: Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am. J. Physiol. Endocrinol. Metab. (2004) 286(2):E261-E271.
  • LIHN AS, RICHELSEN B, PEDERSENSB etal.: Increased expression of TNF-(), IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am. J. Physiol. Endocrinol. Metab. (2003) 285(5):E1072-E1080.
  • HE G, ANDERSEN O, HAUGAARD SB etal.: Plasminogen activator inhibitor type1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines. Eur. J. Clin. Invest. (2005) 35(9):583-590.
  • MYNARCIK DC, COMBS T, MCNURLAN MA, SCHERER PE, KOMAROFF E, GELATO MC: Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J. Acquir. Immune Defic. Syndr. (2002) 31(5):514-520.
  • VIGOUROUX C, MAACHI M, NGUYEN TH etal.: Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS (2003) 17(10):1503-1511.
  • SUZAWA M, TAKADA I, YANAGISAWAJ etal.: Cytokines suppress adipogenesis and PPAR- function through the TAK1/TAB1/NIK cascade. Nat. Cell Biol. (2003) 5(3):224-230.
  • HAUGAARD SB, ANDERSEN O, PEDERSEN SB etal.: Tumor necrosis factor- is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. Metabolism (2006) 55(2):175-182.
  • LIHN AS, PEDERSEN SB, RICHELSENB: Adiponectin: action, regulation and association to insulin sensitivity. Obes. Rev. (2005) 6(1):13-21.
  • ADDY CL, GAVRILA A, TSIODRAS S, BRODOVICZ K, KARCHMER AW, MANTZOROS CS: Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J. Clin. Endocrinol. Metab. (2003) 88(2):627-636.
  • TONG Q, SANKALE JL, HADIGAN CM etal.: Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J. Clin. Endocrinol. Metab. (2003) 88(4):1559-1564.
  • ALESSI MC, PEIRETTI F, MORANGE P, HENRY M, NALBONE G, JUHAN-VAGUE I: Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes (1997) 46(5):860-867.
  • KOHLER HP, GRANT PJ: Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med. (2000) 342(24):1792-1801.
  • YKI-JARVINEN H, SUTINEN J, SILVEIRA A etal.: Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler. Thromb. Vasc. Biol. (2003) 23(4):688-694.
  • YOUNG EM, CONSIDINE RV, SATTLER FR etal.: Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy. Cardiovasc. Toxicol. (2004) 4(2):179-186.
  • WUNDER D, BERSINGER NA, FUX C etal.: Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy. AIDS (2005) 19(16):1837-1842.
  • STEPPAN CM, LAZAR MA: The current biology of resistin. J. Intern. Med. (2004) 255(4):439-447.
  • BARB D, WADHWA SG, KRATZSCH J etal.: Circulating resistin levels are not associated with fat redistribution, insulin resistance, or metabolic profile in patients with the highly active antiretroviral therapy-induced metabolic syndrome. J. Clin. Endocrinol. Metab. (2005) 90(9):5324-5328.
  • GOUGEON ML, PENICAUD L, FROMENTY B, LECLERCQ P, VIARDJP, CAPEAU J: Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir. Ther. (2004) 9(2):161-177.
  • BRINKMAN K, TER HOFSTEDE HJ, BURGER DM, SMEITINK JA, KOOPMANS PP: Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS (1998) 12(14):1735-1744.
  • COTE HC, BRUMME ZL, CRAIB KJ etal.: Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N. Engl. J. Med. (2002) 346(11):811-820.
  • MIURA T, GOTO M, HOSOYA N etal.: Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. J. Med. Virol. (2003) 70(4):497-505.
  • POLO R, MARTINEZ S, MADRIGAL P, GONZALEZ-MUNOZ M: Factors associated with mitochondrial dysfunction in circulating peripheral blood lymphocytes from HIV-infected people. J. Acquir. Immune. Defic. Syndr. (2003) 34(1):32-36.
  • MCCOMSEY GA, PAULSEN DM, LONERGAN JT etal.: Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS (2005) 19(1):15-23.
  • HAUGAARD SB, ANDERSEN O, PEDERSEN SB etal.: Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy. J. Med. Virol. (2005) 77(1):29-38.
  • COSSARIZZA A, PINTI M, MORETTI L etal.: Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophy. J. Infect. Dis. (2002) 185(3):299-305.
  • MCCOMSEY G, TAN DJ, LEDERMANM, WILSON E, WONG LJ: Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS (2002) 16(4):513-518.
  • BRINKMAN K, SMEITINK JA, ROMIJNJA, REISS P: Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet (1999) 354(9184):1112-1115.
  • BAUER AM, STERNFELD T, HORSTERS, SCHUNK M, GOEBELFD, BOGNER JR: Kinetics of lactate metabolism after submaximal ergometric exercise in HIV-infected patients. HIV Med. (2004) 5(5):371-376.
  • MOYLE GJ, DATTA D, MANDALIA S, MORLESE J, ASBOE D, GAZZARD BG: Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS (2002) 16(10):1341-1349.
  • ANDERSEN O, HAUGAARD SB, JORGENSEN LT etal.: Preanalytical handling of samples for measurement of plasma lactate in HIV patients. Scand. J. Clin. Lab. Invest. (2003) 63(6):449-454.
  • DUBE MP, KITCH DW, PARKER RA, ALSTON-SMITH BL, MULLIGAN K: The effect of long-term storage on measured plasma lactate concentrations and prospective lactate results from a multicenter trial of antiretroviral therapy. Clin. Chem. Lab. Med. (2005) 43(9):947-952.
  • NOLAN D, HAMMOND E, JAMES I, MCKINNON E, MALLAL S: Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir. Ther. (2003) 8(6):617-626.
  • WALKER UA, BICKEL M, LUTKEVOLKSBECK SI etal.: Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J. Acquir. Immune Defic. Syndr. (2002) 29(2):117-121.
  • NOLAN D, MALLAL S: Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir. Ther. (2004) 9(6):849-863.
  • HOMMES MJ, ROMIJN JA, ENDERT E, EEFTINCK SCHATTENKERK JK, SAUERWEIN HP: Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism (1991) 40(6):651-656.
  • HADIGAN C, MEIGS JB, CORCORANC etal.: Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin. Infect. Dis. (2001) 32(1):130-139.
  • SABIN C, FRIIS-MOLLER N, REISS P etal.: Risk factors for new onset diabetes mellitus (DM) in HIV patients. 3rd IAS Conference on HIV Pathogenesis and Treatment 2005. Rio de Janeiro, Brazil (2005). Poster abstract no. 2946.
  • BROWN TT, COLE SR, LI X etal.: Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch. Intern. Med. (2005) 165(10):1179-1184.
  • VALCOUR VG, SHIKUMA CM, SHIRAMIZU BT etal.: Diabetes, insulin resistance, and dementia among HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. (2005) 38(1):31-36.
  • GAN SK, SAMARAS K, THOMPSONCH etal.: Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in hiv protease inhibitor-related lipodystrophy. Diabetes (2002) 51(11):3163-3169.
  • LUZI L, PERSEGHIN G, TAMBUSSI G etal.: Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am. J. Physiol. Endocrinol. Metab. (2003) 284(2):E274-E280.
  • SUTINEN J, HAKKINEN AM, WESTERBACKA J etal.: Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS (2002) 16(16):2183-2193.
  • LEE GA, SENEVIRATNE T, NOOR MA etal.: The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS (2004) 18(4):641-649.
  • NOOR MA, LO JC, MULLIGAN K etal.: Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS (2001) 15(7):F11-F18.
  • KUROWSKI M, STERNFELD T, SAWYER A, HILL A, MOCKLINGHOFFC: Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med. (2003) 4(2):94-100.
  • NOOR MA, PARKER RA, OMARA E etal.: The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS (2004) 18(16):2137-2144.
  • BRAMBILLA AM, NOVATI R, CALORIG etal.: Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS (2003) 17(13):1993-1995.
  • BEHRENS GM, BOERNER AR, WEBERK etal.: Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J. Clin. Invest. (2002) 110(9):1319-1327.
  • HAUGAARD SB, ANDERSEN O, MADSBAD S etal.: Skeletal muscle insulin signaling defects downstream of phosphatidylinositol 3-kinase at the level of Akt are associated with impaired nonoxidative glucose disposal in HIV lipodystrophy. Diabetes (2005) 54:3474-3483.
  • CAMMALLERI C, GERMINARIO RJ: The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling. J. Lipid Res. (2003) 44(1):103-108.
  • MURATA H, HRUZ PW, MUECKLERM: Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS (2002) 16(6):859-863.
  • SCHUTT M, ZHOU J, MEIER M, KLEIN HH: Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 -cells. J. Endocrinol. (2004) 183(3):445-454.
  • HAUGAARD SB, ANDERSEN O, STORGAARD H etal.: Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of beta-cells. Am. J. Physiol. Endocrinol. Metab. (2004) 287(4):E677-E685.
  • HAUGAARD SB, ANDERSEN O, HANSEN BR etal.: In nondiabetic, human immunodeficiency virus-infected patients with lipodystrophy, hepatic insulin extraction and posthepatic insulin clearance rate are decreased in proportion to insulin resistance. Metabolism (2005) 54(2):171-179.
  • IOZZO P, PRATIPANAWATR T, PIJL H etal.: Physiological hyperinsulinemia impairs insulin-stimulated glycogen synthase activity and glycogen synthesis. Am. J. Physiol. Endocrinol. Metab. (2001) 280(5):E712-E719.
  • KROGH-MADSEN R, PLOMGAARD P, KELLER P, KELLER C, PEDERSEN BK: Insulin stimulates interleukin-6 and tumor necrosis factor- gene expression in human subcutaneous adipose tissue. Am. J. Physiol. Endocrinol. Metab. (2004) 286(2):E234-E238.
  • FRIIS-MOLLER N, SABIN CA, WEBERR etal.: Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. (2003) 349(21):1993-2003.
  • EL SADR WM, REISS P, DE WIT S etal.: Relationship between prolonged exposure to combination ART and myocardial infarction: effect of sex, age, and lipid changes. 12th Conference on Retrovirus and Opportunistic Infections. Boston, USA (2005). Oral abstract 42.
  • SABIN C, MORFELDT L, FRIIS-MOLLER N etal.: Changes over time in the use of antiretroviral therapy and risk factors for cardiovascular disease in the DAD study. 12th Conference on Retrovirus and Opportunistic Infections. Boston, USA (2005). Poster 866.
  • LAW MG, FRIIS-MOLLER N, EL SADRW etal.: The use of the framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study. HIV Med. (2005) 7(4):218-230.
  • KOPPEL K, BRATT G, SCHULMAN S, BYLUND H, SANDSTROM E: Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. (2002) 29(5):441-449.
  • CURRIER JS, TAYLOR A, BOYD F etal.: Coronary heart disease in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. (2003) 33(4):506-512.
  • KLEIN D, HURLEY LB, QUESENBERRY CP Jr, SIDNEY S: Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J. Acquir. Immune Defic. Syndr. (2002) 30(5):471-477.
  • MARY-KRAUSE M, COTTE L, SIMONA, PARTISANI M, COSTAGLIOLA D: Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS (2003) 17(17):2479-2486.
  • BOZZETTE SA, AKE CF, TAM HK, CHANG SW, LOUIS TA: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J. Med. (2003) 348(8):702-710.
  • HSUE PY, LO JC, FRANKLIN A etal.: Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation (2004) 109(13):1603-1608.
  • STEIN JH, KLEIN MA, BELLEHUMEUR JL etal.: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation (2001) 104(3):257-262.
  • TEBAS P, POWDERLY WG, CLAXTONS etal.: Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 14(4):F63-F67.
  • MONDY K, YARASHESKI K, POWDERLY WG etal.: Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin. Infect. Dis. (2003) 36(4):482-490.
  • WANG MW, WEI S, FACCIO R etal.: The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J. Clin. Invest. (2004) 114(2):206-213.
  • COZZOLINO M, VIDAL M, ARCIDIACONO MV, TEBAS P, YARASHESKI KE, DUSSO AS: HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS (2003) 17(4):513-520.
  • CARR A, SAMARAS K, CHISHOLM DJ, COOPER DA: Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet (1998) 351(9119):1881-1883.
  • SHAH M, TIERNEY K, ADAMS-HUET B etal.: The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with lipodystrophy. HIV Med. (2005) 6(4):291-298.
  • WOHL DA, TIEN HC, BUSBY M etal.: Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin. Infect. Dis. (2005) 41(10):1498-1504.
  • HENDRICKS KM, DONG KR, TANGAM etal.: High-fiber diet in HIV-positive men is associated with lower risk of developing fat deposition. Am. J. Clin. Nutr. (2003) 78(4):790-795.
  • THONI GJ, FEDOU C, BRUN JF etal.: Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. Diabetes Metab. (2002) 28(5):397-404.
  • GRINSPOON S, CARR A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. (2005) 352(1):48-62.
  • MARTINEZ E, ARNAIZ JA, PODZAMCZER D etal.: Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N. Engl. J. Med. (2003) 349(11):1036-1046.
  • MOYLE GJ, BALDWIN C, LANGROUDI B, MANDALIA S, GAZZARD BG: A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J. Acquir. Immune Defic. Syndr. (2003) 33(1):22-28.
  • NEGREDO E, RIBALTA J, PAREDES R etal.: Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS (2002) 16(10):1383-1389.
  • MARTIN A, SMITH DE, CARR A etal.: Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS (2004) 18(7):1029-1036.
  • MCCOMSEY GA, WARD DJ, HESSENTHALER SM etal.: Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin. Infect. Dis. (2004) 38(2):263-270.
  • MOYLE GJ, SABIN C, CARTLEDGE J etal.: A 48-week, randomized, open-label comparative study of tenofovir DF versus abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART. 12th Conference on Retrovirus and Opportunistic Infections. Boston, USA (2005). Abstract LB 44.
  • HANSEN BR, HAUGAARD SB, IVERSEN J, NIELSEN JO, ANDERSENO: Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review. Scand. J. Infect. Dis. (2004) 36(4):244-253.
  • PAI N, TULSKY J, LAWRENCE J, COLFORD J Jr, REINGOLD A, PAI NM: Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst. Rev. (2005) 4:CD005482.
  • MILINKOVIC A, LOPEZ S, VIDAL S etal.: A randomized open study comparing the effect of reducing stavudine dose versus switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine. 12th Conference on Retrovirus and Opportunistic Infections. Boston, USA (2005). Abstract 857.
  • CARR A, WORKMAN C, CAREY D etal.: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet (2004) 363(9407):429-438.
  • HADIGAN C, YAWETZ S, THOMAS A, HAVERS F, SAX PE, GRINSPOON S: Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann. Intern. Med. (2004) 140(10):786-794.
  • SUTINEN J, HAKKINEN AM, WESTERBACKA J etal.: Rosiglitazone in the treatment of HAART-associated lipodystrophy a randomized double-blind placebo-controlled study. Antivir. Ther. (2003) 8(3):199-207.
  • VAN WIJK JP, DE KONING EJ, CABEZAS MC etal.: Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann. Intern. Med. (2005) 143(5):337-346.
  • GAVRILA A, HSU W, TSIODRAS S etal.: Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin. Infect. Dis. (2005) 40(5):745-749.
  • RASOULI N, RAUE U, MILES LM etal.: Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am. J. Physiol. Endocrinol. Metab. (2005) 288(5):E930-E934.
  • SLAMA L, LANOY E, VALENTIN M etal.: Effect of pioglitazone on HIV-1 related lipoatrophy: a randomized double-blind placebo-controlled trial (ANRS 113) with 130 patients. 13th Conference on Retrovirus and Opportunistic Infections. Denver, USA (2006). Abstract 151LB.
  • HADIGAN C, RABE J, GRINSPOON S: Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J. Clin. Endocrinol. Metab. (2002) 87(10):4611-4615.
  • MARTINEZ E, DOMINGO P, RIBERA E etal.: Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. Antivir. Ther. (2003) 8(5):403-410.
  • CALZA L, MANFREDI R, CHIODO F: Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS (2003) 17(6):851-859.
  • NISSEN SE, WOLSKI K, TOPOL EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. JAMA (2005) 294(20):2581-2586.
  • ENGELSON ES, GLESBY MJ, MENDEZD etal.: Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J. Acquir. Immune. Defic. Syndr. (2002) 30(4):379-391.
  • KOTLER DP, MUURAHAINEN N, GRUNFELD C etal.: Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J. Acquir. Immune. Defic. Syndr. (2004) 35(3):239-252.
  • LO JC, MULLIGAN K, NOOR MA etal.: The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J. Clin. Endocrinol. Metab. (2001) 86(8):3480-3487.
  • HAUGAARD SB, ANDERSEN O, HANSEN BR etal.: Insulin-like growth factors, insulin-like growth factor-binding proteins, insulin-like growth factor-binding protein-3 protease, and growth hormone-binding protein in lipodystrophic human immunodeficiency virus-infected patients. Metabolism (2004) 53(12):1565-1573.
  • ANDERSEN O, HAUGAARD SB, FLYVBJERG A etal.: Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study. Eur. J. Clin. Invest. (2004) 34(8):561-568.
  • LO JC, MULLIGAN K, NOOR MA etal.: The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study. Clin. Infect. Dis. (2004) 39(5):732-735.
  • KOUTKIA P, CANAVAN B, BREU J, TORRIANI M, KISSKO J, GRINSPOONS: Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA (2004) 292(2):210-218.
  • PIKETTY C, JAYLE D, GONZALEZ-CANALI G, DEBUIRE B, BAULIEU EE, KAZATCHKINE MD: Low plasma levels of dehydroepiandrosterone (DHEA) and incidence of lipodystrophy. HIV Med. (2001) 2(2):136-138.
  • SMITH KJ, SKELTON HG: Peroxisomal proliferator-activated ligand therapy for HIV lipodystrophy. Clin. Exp. Dermatol. (2001) 26(2):155-161.
  • WALKER UA, VENHOFF N: Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity. Antivir. Ther. (2005) 10(Suppl.2):M117-M123.
  • SUTINEN J, WALKER UA, HKKINENAM, RISTOLA M, YKI-JARVINEN H: Uridine for the treatment of HAART-associated lipodystrophy a randomized, double-blind, placebo-controlled trial. 10th European AIDS Conference/EACS. Dublin, Ireland (2005). Abstract PS5/6.
  • CLARK R: The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Endocr. Rev. (1997) 18(2):157-179.
  • NAPOLITANO LA, LO JC, GOTWAYMB etal.: Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS (2002) 16(8):1103-1111.
  • PIRES A, PIDO-LOPEZ J, MOYLE G, GAZZARD B, GOTCH F, IMAMI N: Enhanced T-cell maturation, differentiation and function in HIV-1-infected individuals after growth hormone and highly active antiretroviral therapy. Antivir. Ther. (2004) 9(1):67-75.
  • ANDERSEN O, HAUGAARD SB, HANSEN BR etal.: Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy. Scand. J. Infect. Dis. (2004) 36(11-12):832-839.
  • HAUGAARD SB, ANDERSEN O, FLYVBJERG A, ORSKOV H, MADSBADS, IVERSEN J: Growth factors, glucose and insulin kinetics after low dose growth hormone therapy in HIV-lipodystrophy. J. Infect. (2005) (In Press).
  • PETERLIK M, CROSS HS: Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur. J. Clin. Invest. (2005) 35(5):290-304.
  • HAUG CJ, AUKRUST P, HAUG E, MORKRID L, MULLER F, FROLANDSS: Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J. Clin. Endocrinol. Metab. (1998) 83(11):3832-3838.
  • NIETO G, BARBER Y, RUBIO MC, RUBIO M, FIBLA J: Association between AIDS disease progression rates and the Fok-I polymorphism of the VDR gene in a cohort of HIV-1 seropositive patients. J. Steroid Biochem. Mol. Biol. (2004) 89-90(1-5):199-207.
  • COLLAZOS J, MARTINEZ E, MAYO J, IBARRA S: Sexual hormones in HIV-infected patients: the influence of antiretroviral therapy. AIDS (2002) 16(6):934-937.
  • PEDERSEN SB, BRUUN JM, HUBE F, KRISTENSEN K, HAUNER H, RICHELSEN B: Demonstration of estrogen receptor subtypes and in human adipose tissue: influences of adipose cell differentiation and fat depot localization. Mol. Cell Endocrinol. (2001) 182(1):27-37.
  • ANDERSEN O, HAUGAARD SB, RATHJE GS etal.: Do sex hormones contribute to insulin resistance and fat redistribution in antiretroviral treated male HIV patients? 3rd European Workshop on lipodystropjy and metabolic disorders. Marbella, Spain (2002). Abstract O15.
  • KREIER F, FLIERS E, VOSHOL PJ etal.: Selective parasympathetic innervation of subcutaneous and intra-abdominal fat-functional implications. J. Clin. Invest. (2002) 110(9):1243-1250.
  • FLIERS E, SAUERWEIN HP, ROMIJN JA etal.: HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy. Lancet (2003) 362(9397):1758-1760.
  • VAN DER VALK M, REISS P, VANLETHFC etal.: Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure. J. Clin. Endocrinol. Metab. (2002) 87(11):5066-5071.
  • SUTINEN J, KANNISTO K, KORSHENINNIKOVA E etal.: In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushings syndrome is associated with increased regeneration of cortisol by 11-hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia (2004) 47(10):1668-1671.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.